When topicals fall short, oral Janus kinase inhibitors offer a needed solution in chronic hand eczema
Saved in:
| Main Author: | Christopher G. Bunick, MD, PhD |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-10-01
|
| Series: | JAAD International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666328725000793 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib
by: Luo Y, et al.
Published: (2025-05-01) -
Comparative Analysis of the Efficacy of Abrocitinib and Dupilumab in the Treatment of Atopic Dermatitis
by: Song D, et al.
Published: (2025-04-01) -
Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis
by: Grace Xiong, BHSc, et al.
Published: (2025-04-01) -
A Practical Approach to Chronic Hand Eczema
by: Sophia A. Mense, et al.
Published: (2025-05-01) -
Systematic Literature Review and Network Meta-Analysis of Clinical Efficacy and Safety of Topical Treatments for Patients with Atopic Dermatitis
by: Hiroyuki Murota, et al.
Published: (2025-03-01)